Techcyte, a digital diagnostics company providing AI-powered pathology solutions, announced a $15 million funding round led by Van Tuyl Companies, with participation from Zoetis Inc. and Mayo Clinic.
The investment supports strategic growth and advances the company’s path to profitability, with the veterinary segment already profitable and other divisions expected to follow next year.
AI Platform for Digital Pathology
Techcyte’s Fusion platform integrates AI, digital workflows, and laboratory systems to improve efficiency, standardize processes, and enable scalable diagnostics. The solution addresses increasing pressure on laboratories facing higher test volumes, limited resources, and workforce shortages.
“Laboratories are being asked to do more with less, while maintaining high standards for quality and rapid turnaround times,” said Ben Cahoon, CEO of Techcyte. “Techcyte Fusion® directly addresses these challenges through unified AI-enabled pathology workflows. This investment allows us to continue growing the Fusion platform and extending the world-class capabilities that were built in collaboration with Mayo Clinic. We are grateful to Van Tuyl Companies for leading this round and to Mayo Clinic and Zoetis for their continued collaboration and support.”
Data and Technology Expansion
The funding also provides access to Mayo Clinic’s Safe Harbor dataset, including more than 17 million de-identified slides and pathology reports, strengthening AI model development and diagnostic capabilities.
Market Impact
By applying AI to routine pathology workflows, Techcyte aims to improve diagnostic accuracy, reduce turnaround times, and expand access to expertise through digital and remote operations.